
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **September 18, 2018**



ENDONOVO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-55453
(Commission
File Number)

45-2552528
(IRS Employer
Identification No.)

6320 Canoga Avenue, 15th Floor
Woodland Hills, CA 91367
(Address of principal executive office)(Zip Code)

Registrant's telephone number, including area code: **(800) 489-4774**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 3.03 Material Modification to Rights of Security Holders.

On September 18, 2018, the Registrant filed a certificate of amendment to its certificate of incorporation to increase the number of shares of common stock which it may issue from 500,000,000 to 2,500,000,000. The amendment was approved by over 60% of the voting power of the Registrant.

Item 9.01 Financial Statements and Exhibits.

- (a) Financial Statements -None
- (b) Exhibits

3.1 [Certificate of Amendment](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 24, 2018

ENDONOVO THERAPEUTICS, INC.

By: /s/ Alan Collier

Alan Collier
Chief Executive Officer

**CERTIFICATE OF AMENDMENT OF
THE CERTIFICATE OF INCORPORATION
OF
ENDONOVO THERAPEUTICS, INC.**

It is hereby certified that:

1. The name of the corporation (hereinafter called the "corporation") is: Endonovo Therapeutics, Inc.

2. The certificate of incorporation of the corporation is hereby amended by striking out Article the First Sentence of Article Fourth thereof and by substituting in lieu of said first sentence of Article Fourth the following new first sentence of Article Fourth:

The total number of shares of all classes of stock which the Corporation shall have authority to issue is Two Billion Five Million (2,505,000,000) shares of which Five Million (5,000,000) shares shall be Preferred Stock, par value \$.0001 per share, and Two Billion (2,500,000,000) shall be Common Stock, par value \$.0001 per share. The voting power, designations, preferences and relative participating option or other special qualifications, limitations or restrictions are set forth hereinafter:

3. The amendment of the certificate of incorporation herein certified has been duly adopted and written consent has been given in accordance with the provisions of Sections 228 and 242 of the General Corporation Law of the State of Delaware.

Signed on September 18, 2018



Alan Collier, CEO

